Chempartner Pharmatech Past Earnings Performance
Past criteria checks 0/6
Chempartner Pharmatech's earnings have been declining at an average annual rate of -20.6%, while the Biotechs industry saw earnings growing at 5.2% annually. Revenues have been growing at an average rate of 4.1% per year.
Key information
-20.6%
Earnings growth rate
-20.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 4.1% |
| Return on equity | -29.1% |
| Net Margin | -60.1% |
| Next Earnings Update | 26 Apr 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Chempartner Pharmatech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1,141 | -686 | 231 | 71 |
| 30 Jun 23 | 1,197 | -600 | 254 | 72 |
| 31 Mar 23 | 1,209 | 341 | 301 | 85 |
| 31 Dec 22 | 1,327 | 379 | 323 | 92 |
| 30 Sep 22 | 1,461 | 606 | 370 | 114 |
| 30 Jun 22 | 1,532 | 549 | 377 | 124 |
| 31 Mar 22 | 1,687 | -394 | 354 | 128 |
| 01 Jan 22 | 1,691 | -402 | 337 | 125 |
| 30 Sep 21 | 1,674 | 86 | 305 | 117 |
| 30 Jun 21 | 1,657 | 119 | 286 | 109 |
| 31 Mar 21 | 1,593 | 170 | 294 | 88 |
| 31 Dec 20 | 1,482 | 155 | 285 | 72 |
| 30 Sep 20 | 1,443 | 141 | 314 | 19 |
| 30 Jun 20 | 1,383 | 131 | 319 | 8 |
| 31 Mar 20 | 1,309 | 99 | 309 | 10 |
| 31 Dec 19 | 1,328 | 139 | 304 | 11 |
| 30 Sep 19 | 1,330 | 130 | 297 | 50 |
| 30 Jun 19 | 1,352 | 156 | 285 | 46 |
| 31 Mar 19 | 1,215 | 176 | 248 | 34 |
| 31 Dec 18 | 997 | 161 | 210 | 27 |
| 30 Sep 18 | 701 | 120 | 138 | 20 |
| 30 Jun 18 | 409 | 79 | 84 | 22 |
| 31 Mar 18 | 303 | 56 | 67 | 18 |
| 31 Dec 17 | 275 | 58 | 57 | 15 |
| 30 Sep 17 | 264 | 61 | 55 | 10 |
| 30 Jun 17 | 263 | 66 | 57 | 0 |
| 31 Mar 17 | 256 | 62 | 57 | 0 |
| 31 Dec 16 | 259 | 65 | 57 | 0 |
| 30 Sep 16 | 252 | 58 | 60 | 0 |
| 30 Jun 16 | 274 | 66 | 71 | 0 |
| 31 Mar 16 | 302 | 63 | 79 | 0 |
| 31 Dec 15 | 319 | 59 | 88 | 0 |
| 30 Sep 15 | 318 | 62 | 93 | 0 |
| 30 Jun 15 | 309 | 47 | 94 | 0 |
| 31 Mar 15 | 295 | 45 | 92 | 0 |
| 31 Dec 14 | 281 | 41 | 89 | 0 |
| 30 Sep 14 | 269 | 42 | 85 | 0 |
| 30 Jun 14 | 260 | 38 | 80 | 0 |
| 31 Mar 14 | 256 | 39 | 74 | 0 |
| 31 Dec 13 | 257 | 40 | 72 | 0 |
| 30 Sep 13 | 256 | 37 | 64 | 0 |
| 30 Jun 13 | 247 | 36 | 58 | 0 |
Quality Earnings: 300149 is currently unprofitable.
Growing Profit Margin: 300149 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300149 is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare 300149's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300149 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.6%).
Return on Equity
High ROE: 300149 has a negative Return on Equity (-29.14%), as it is currently unprofitable.